Navigation Links
Hospira Receives Favorable Court Decision on Eloxatin(R)
Date:6/18/2009

-- Has Tentative FDA Approval and Expects Final Approval Shortly --

LAKE FOREST, Ill., June 18 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced that the U.S. District Court for the District of New Jersey has granted summary judgment of non-infringement in Hospira's favor with regard to Sanofi Aventis' chemotherapy medication Eloxatin(R), and that Hospira has tentative approval from the U.S. Food and Drug Administration (FDA) for its generic version of the product. Hospira expects full FDA approval shortly.

Hospira's version of Eloxatin, which goes by the generic name oxaliplatin injection, will be one of the first generic versions available in the United States to come in solution form. U.S. sales of Eloxatin last year were approximately $1.4 billion.

"We are extremely pleased with the court's ruling," said Joshua Gordon, vice president, Specialty Pharmaceuticals, Hospira. "The launch of Hospira's oxaliplatin injection will provide a high-quality, lower-cost alternative to patients, and is another example of Hospira working to meet patient and caregiver needs in the fast-growing oncology market."

Hospira's specialty injectable pharmaceuticals (SIP) offering includes approximately 200 generic injectable drugs in many dosages and formulations. In addition, many of its products are available in popular differentiated formats, several of which are proprietary, such as its ADD-Vantage Drug Delivery System and iSecure(R) prefilled syringes. Therapeutic segments include anesthesia, anti-infectives, analgesics, cardiovascular, oncology, emergency and other areas. Hospira has approximately 25 generic drugs scheduled to launch in various regions around the world in 2009 and 2010.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has more than 14,000 employees. Learn more at www.hospira.com.

                Private Securities Litigation Reform Act of 1995 --
                 A Caution Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including projections of certain measures of Hospira's results of operations, projections of certain charges and expenses, and other statements regarding Hospira's goals and strategy. Hospira cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Hospira's operations and may cause actual results to be materially different from expectations include the risks, uncertainties and factors discussed under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Hospira's latest Annual Report on Form 10-K filed with the Securities and Exchange Commission, which is incorporated by reference. Hospira undertakes no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Hospira Announces Plans to Integrate Symbiq(R) and EndoTool(R) Technologies
2. Hospira Names Brian Meadows Supply Chain Chief
3. Hospira Supports Newly Introduced Biogenerics Legislation
4. Hospira Advances Patient Safety With New GemStar(R) SP Infusion System
5. StemCor Signs Agreement With Hospira to Market New Medical Device to Oncologists and Hematologists
6. Hospira Hosts Conference Call for Third-Quarter 2008 Earnings
7. Human Genome Sciences Announces Process Development and Manufacturing Alliance With Hospira
8. Hospira Expands Board of Directors
9. Hospiras Biosimilar Epoetin Retacrit(TM) Receives Positive Opinion Recommending EU Approval
10. Biogenerics Will Save Billions, Says Hospira CEO
11. Berlin Heart Inc. Receives FDA Orphan Product Development Grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... DuPont Pioneer ... that they have entered into a multiyear collaboration to identify and characterize novel ... additional tools for gene editing across all applications. , Under the terms of ...
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, a global ... industries to improve patient outcomes and quality of life, will now be offering ... being attributed to new regulatory requirements for all new drug products, including the ...
(Date:10/11/2017)... LINDA, CA (PRWEB) , ... October 11, 2017 ... ... to upregulate any gene in its endogenous context, enabling overexpression experiments and avoiding ... (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function studies. ...
(Date:10/11/2017)... ... 11, 2017 , ... Proscia Inc ., a data ... titled, “Pathology is going digital. Is your lab ready?” with Dr. Nicolas Cacciabeve, ... and how Proscia improves lab economics and realizes an increase in diagnostic confidence.* ...
Breaking Biology Technology:
(Date:5/23/2017)... -- Hunova, the first robotic gym for the rehabilitation and functional motor sense ... Genoa, Italy . The first 30 robots will be available ... USA . The technology was developed and patented at the IIT ... Movendo Technology thanks to a 10 million euro investment from entrepreneur Sergio ... ...
(Date:4/24/2017)... , April 24, 2017 ... and partner with  Identity Strategy Partners, LLP (IdSP) ... "With or without President Trump,s March 6, 2017 ... Terrorist Entry , refugee vetting can be instilled with ... resettlement. (Right now, all refugee applications are suspended ...
(Date:4/13/2017)... April 13, 2017 UBM,s Advanced Design and ... will feature emerging and evolving technology through its 3D ... will run alongside the expo portion of the event ... and demonstrations focused on trending topics within 3D printing ... and manufacturing event will take place June 13-15, 2017 at ...
Breaking Biology News(10 mins):